Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-01
2008-01-01
Kwon, Brian (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S266400, C514S253010
Reexamination Certificate
active
10749437
ABSTRACT:
The present invention relates to compositions and methods of treatment for cardioprotection through the use of non-peptidic delta opioid receptor agonist compound(s) that mediate cardioprotective effects of ischemic preconditioning. The compounds are used to reduce injury associated with ischemia and reperfusion of cardiac tissue. Further, the compounds may be used in solutions preserving the viability of an isolated organ.
REFERENCES:
patent: 5656420 (1997-08-01), Chien
patent: 5658908 (1997-08-01), Chang et al.
patent: 5854249 (1998-12-01), Chang et al.
patent: 6026817 (2000-02-01), Clemens
patent: 6103722 (2000-08-01), Schultz et al.
patent: 6200978 (2001-03-01), Maw et al.
patent: 6262062 (2001-07-01), Clemens
patent: 6444679 (2002-09-01), Liras et al.
patent: 6503905 (2003-01-01), Liras et al.
patent: 6645938 (2003-11-01), Oeltgen et al.
patent: 6919350 (2005-07-01), Chang et al.
patent: 6924288 (2005-08-01), Chang
patent: 6960609 (2005-11-01), McHardy et al.
patent: 2002/0045636 (2002-04-01), Clemens
patent: 2002/0052007 (2002-05-01), Chang et al.
patent: 2003/0186872 (2003-10-01), Chang et al.
patent: 2004/0002503 (2004-01-01), Chang et al.
patent: WO 99/01438 (1999-01-01), None
“NIH Heart Disease & Stroke Research: Fact Sheet”, American Heart Association 2004.
Cardiovascular Disease:Treatment for Stroke, Standford Hospital & Clinics, 2003.
“Heart Disease”, Charlotte E. Grayson, WebMD, 2004.
“Acute Congestive Heart Failure”, Thomas N. Levin, Postgraduate Medicine, vol. 101, No. 1, 1997.
Ito et al., “U-92032, a T-type Ca2+channel blocker and antioxidant, reduces neuronal ischemic injuries”, European Journak of Pharmacology, (1994), 257, 203-325.
Patel, Hemal H., et al. “BW373U86, a δ Opioid Agonist, Partially Mediates Delayed Cardioprotection via a Free Radical Mechanism that is Independent of Opioid Receptor Stimulation.” Journal of Molecular Cell Cardiology, vol. 33, (2001), pp. 1455-1465.
Patel, Hemal H., et al. “Delta opioid agonists and volatile anesthetics facilitate cardioprotection via potentiation of KATPchannel opening.” FASEB J., vol. 16, (2002),pp. 1468-1470.
Lasukova, T. V., et al. “Effect of in Vivo and in Vitro Stimulation of δl-Opioid Receptors on Myocardial Resistance to Arrhythmogenic Action of Ischemia and Reperfusion.” Bulletin of Experimental Biology and Medicine, No. 4, (2002), pp. 359-362.
Murry, C.E. et al. “Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.” Abstract from Circulation, vol. 74, No. 5, (1986), pp. 1124-1136.
Chang Kwen-Jen
Gengo Peter J.
Ma Xin
Pendergast William
Fuierer Marianne
Kwon Brian
Moore & Van Allen PLLC
Mount Cook Biosciences, Inc.
Wagner Eric F.
LandOfFree
Cardioprotective delta opioid receptor agonists and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cardioprotective delta opioid receptor agonists and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cardioprotective delta opioid receptor agonists and methods... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3933165